

April 7, 2025

PDRadiopharma Inc.

## Further Enhancements Added to the “onti” Medical Isotope Exposure Dose Management System

*\*This release is an English translation of “第2報 医療被ばく線量管理システム「onti」にさらなる機能拡張を追加”, with a priority given to Japanese for content and interpretation. The indication is specifically for Japan only and not for other countries.*

TOKYO, JAPAN – April 7, 2025 - PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, “PDRadiopharma”) is pleased to announce the second round of feature enhancements to its medical isotope exposure dose management system, “onti”. Building on the functionality previously announced on March 17, 2025, these newly added features include “Automatic Calculation of Appropriate Dosage for Pediatric Nuclear Medicine Examinations” and “Viewing Procedure Manuals for Labeling with Radioactive Isotopes”. These additional features will be available starting April 11, 2025.

### **New Features 1: Automatic Calculation of Appropriate Dosage for Pediatric Nuclear Medicine Examinations**

- The dosage calculation method proposed in Japanese Consensus Guidelines for the Proper Implementation of Pediatric Nuclear Medicine Examinations 2020<sup>†</sup> (hereinafter referred to as ‘The Guidelines’) has been incorporated into “onti”.
- By interfacing with the hospital's test scheduling system, “onti” automatically calculates the appropriate dosage.

This feature simplifies the process of verifying The Guidelines and calculating the appropriate dosage, helping to prevent calculation errors and improve operational efficiency.

### **New Features 2: Viewing Procedure Manuals for Labeling with Radioactive Isotopes**

- You can easily confirm the procedures and precautions for labeling with radioactive isotopes using “onti”.
- Reduces the need to search for and store printed booklet-type procedure manuals.

This feature enables hospitals to quickly access Radioisotope labeling and preparation procedures and precautions using “onti”, eliminating the need to search for printed booklets and saving storage space.

Beyond the supply of radiopharmaceuticals, we are committed to solving information management challenges by integrating data and digital technologies with medical DX solutions. We will continue to contribute to the advancement of safe and efficient radiopharmaceutical medicine while delivering higher-quality services.

\* “onti” is an information system that supports electronic recording, management, and optimization of radiation exposure. It has been sold by PDRadiopharma since October 2023.

<sup>†</sup> The Japanese Society of Nuclear Medicine, Japanese Consensus Guidelines for the Proper Implementation of Pediatric Nuclear Medicine Examinations 2020

### **About PDRadiopharma**

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals, since it started its business in 1968. Currently PDRadiopharma offers 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit <https://www.pdradiopharma.com/>

Inquiries:

PDRadiopharma Inc.

Contact: Akiko Murakami, General Affairs

Email: [s-info-hq@pdradiopharma.com](mailto:s-info-hq@pdradiopharma.com)